Page 4

TheLaboratoryReport_Winter2014

THE LABORATORY REPORT Winter 2014 Page 4 American Society for Investigative Pathology to Convene in San Diego The American Society for Investigative Pathology (ASIP) will hold its 2014 annual meeting on April 26th – 30th at the San Diego Convention Center in San Diego, California. As current president of the ASIP, Dr. James M. Musser, chair of the Department of Pathology and Genomic Medicine, will preside over an exciting and diverse agenda. The ASIP meeting will focus on the pathobiology of disease, and symposia topics include “Personalized Medicine Therapies for Lung Cancer“ and “Genomic-Scale Analysis of Single Cells”. Several department faculty are attending and will present their research findings. For a full list of speakers and topics, or to register, please visit: http://www.asip.org/meetings/2014/index.cfm New Tests Available from Houston Methodist Diagnostic Laboratory Anti-Xa Rivaroxaban (Xarelto®) Levels Rivaroxaban (Xarelto®) is a new oral anticoagulant designed to replace warfarin for patients with venous thrombosis or thrombosis associated with atrial fibrillation. Rivaroxaban does not require routine monitoring, but measurement of levels may be useful for patients with bleeding or thrombosis while tak-ing the medication or for clearance prior to surgery. Available stat 24/7. Sample: frozen citrate plasma. For more details or ordering information, please contact Sara Hanzel (sbhanzel@ houstonmethodist.org) or Dr. Wayne Chandler (wlchandler@ houstonmethodist.org). MLPA Assay to Detect Oligodendroglioma Biomarkers Oligodendrogliomas are a type of primary brain tumor that can be difficult to diagnose. Distinguishing oligodendroglio-mas from other primary brain tumors based solely on histology, or how the tumors appear under a microscopic, is challenging. However, this distinction is clinically important as it affects treatment and prognosis: oligodendrogliomas frequently respond favorably to chemotherapy and are associated with longer survival. Detecting loss of part of chromosome 1 and 19 (1p & 19q) provides a molecular signature that is strongly associ-ated with oligodendrogliomas. In addition to chromosome loss, oligodendrogliomas also commonly have mutations in the IDH1 or IDH2 gene, and patients with these mutations typically have better outcomes than patients without. A new molecular assay offered by the Houston Methodist Department of Pathology and Genomic Medicine’s Molecular Di-agnostic Laboratory uses an efficient and streamlined approach to detect both chromosome loss (1p and 19q) and gene mutation (IDH1 and IDH2) in a single assay. The technology is referred to as “Multiplex Ligation-dependent Probe Amplification” or MLPA. The technique simultaneously uses DNA probes that recognize changes in chromosome 1, chromosome 19, IDH1, and IDH2, all in a single assay. It is currently available and run weekly to provide rapid turnaround times. For more information on these assays or any molecular diagnostic laboratory test, please contact Dr. Bryce Portier (bpportier@houstonmethodist.org) or Dr. Randall Olsen (rjolsen@houstonmethodist.org). MLPA is highly sensititve and accurate, and can detect abnormal chromosomal copy numbers or single nucleotide differences in genes. Image from FisherBiotec.com


TheLaboratoryReport_Winter2014
To see the actual publication please follow the link above